Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers
NCT ID: NCT02571738
Last Updated: 2017-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
108 participants
INTERVENTIONAL
2015-10-31
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CHAM
Cryopreserved Human Amniotic Membrane
CHAM
The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
Control
Standard of Care
Control
Standard of Care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CHAM
The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
Control
Standard of Care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmed diagnosis of Type I or Type II Diabetes
3. An Index Ulcer defined as chronic (presence of wound for \> 4 weeks), but not present for more than 52 weeks at the Screening Visit
4. Index Ulcer is located below the malleoli on the plantar or dorsal surface of the foot
5. The Index Ulcer is between 1 cm2 and 15 cm2, inclusive, at the Screening Visit
6. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule
7. Wound is free of necrotic debris
8. Patient has adequate circulation to the foot as documented by either:
* Ankle Brachial Index (ABI) \> 0.70 and \< 1.30, or
* In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30, a Toe Brachial Index (TBI) ≥ 0.50, or
* In patients with non-compressible ankle vessels defined as an ABI ≥ 1.30 and TBI cannot be performed (e.g., toe is absent, wounds are present, or site cannot perform a TBI), a Doppler waveform in the posterior tibial or dorsalis pedis arteries at the ankle consistent with adequate flow in the foot (biphasic or triphasic) and other diagnostic confirmation of adequate flow (e.g., duplex imaging, normal pulse volume recording \[PVR\] testing).
Exclusion Criteria
2. Gangrene is present on any part of the affected foot
3. Index Ulcer is over an active Charcot deformity
4. The longest dimension of the Index Ulcer exceeds 5 cm at the Baseline Visit
5. Patient is currently receiving dialysis or planning to go on dialysis
6. Patient has had 2 or more previous disease-related amputations of the lower extremities
7. Patient has a glycated hemoglobin A1c (HbA1c) level of \>10%
8. Chronic oral steroid use \>7.5 mg daily for longer than 3 months at the time of screening
9. Patient is receiving IV corticosteroids, immunosuppressive or cytotoxic agents at the time of screening
10. Requiring intravenous (IV) antibiotics to treat the index wound infection at the time of screening
11. Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration
12. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
13. Current evidence of cellulitis, or other evidence of infection including fever or pus drainage from the wound site
14. Current evidence of osteomyelitis or history of osteomyelitis within 30 days of screening
15. Patient has active malignancy other than non-melanoma skin cancer
16. Patient's Index Ulcer has decreased by ≥20% during 1-week screening period
17. Patient's random blood sugar is \>350 mg/dl at screening
18. Patient has untreated alcohol or substance abuse at the time of screening
19. Pregnant women and women who are breastfeeding
20. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening
21. Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies
22. Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study
23. Patients who have already been randomized in Protocol 303 at any center may not be considered for screening or for re-entry into the trial at any center, even after the end of their follow-up period
24. Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Osiris Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SAVAHCS
Tucson, Arizona, United States
ILD Research Center
Carlsbad, California, United States
Center for Clinical Research
Castro Valley, California, United States
Center for Clinical Research
San Francisco, California, United States
Stanford University
Stanford, California, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Barry University Clinical Research
North Miami Beach, Florida, United States
SSH
South Weymouth, Massachusetts, United States
Ocean County Foot & Ankle Surgical Associates
Toms River, New Jersey, United States
NSLIJHS
Lake Success, New York, United States
UNC
Chapel Hill, North Carolina, United States
Duke University
Durham, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
University Orthopedics
Altoona, Pennsylvania, United States
Temple University
Philadelphia, Pennsylvania, United States
Spartanburg Regional Healthcare System
Spartanburg, South Carolina, United States
North Texas Podiatric Medicine and Surgery Associates
Dallas, Texas, United States
Texas Gulf Coast Medical Group
Webster, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Osiris Protocol 303
Identifier Type: -
Identifier Source: org_study_id